Panc-1 Cancer Cells
Panc-1 Cancer Cells - Related Videos
09:22
Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
0 Views •
Cited by 44 •
2017
Here, we describe xenograft zebrafish models using two different injection sites, i.e., perivitelline space and duct of Cuvier, to investigate the invasive behavior and to assess the intravasation and extravasation potential of human breast cancer cells, respectively.
07:59
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
0 Views •
Cited by 1 •
2020
Ovarian cancer stem cells (OCSC) are responsible for cancer initiation, recurrence, therapeutic resistance, and metastasis. The OCSC vascular niche is considered to promote self-renewal of OCSCs, leading to chemoresistance. This protocol provides the basis for establishing a reproducible OCSC vascular niche model in vitro.
12:55
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
0 Views •
Cited by 11 •
2017
This manuscript describes standard protocols for measuring tau hyperphosphorylation, measuring tau binding to microtubules, and localization of intracellular tau following drug treatments. These protocols can be used repetitively for screening drugs or other compounds that target tau hyperphosphorylation or microtubule binding.
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
0 Views •
Cited by 6 •
2014
The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
0 Views •
Cited by 27 •
2015
Pancreatic cancer stem cells (CSCs) can be expanded in vitro using the anchorage-independent sphere culture technique, which represents a powerful tool to study CSC biology and can serve as the first step to develop novel CSC-targeting therapies. Here the methodology for expanding, analyzing and targeting of pancreatic CSCs is provided.
FAQs
The KRAS G12D alteration can sustain MAPK and PI3K-AKT signaling, two pathways linked in this model to proliferation and invasive behavior. This makes the cells useful for examining how oncogenic signaling contributes to pancreatic cancer phenotypes. Experiments can then connect pathway activity with changes in cell growth or responses to targeted and cytotoxic treatments.
Poor differentiation makes PANC-1 cells useful for studying tumor-cell states associated with epithelial-to-mesenchymal transition, or EMT. Researchers can investigate how cells display changes linked to migration and invasion, rather than focusing only on proliferation. The model therefore supports mechanistic comparisons of tumor behavior under different experimental conditions.
Results provide controlled evidence about pancreatic cancer cell biology, but they do not capture every feature of a patient tumor. The line is a reproducible in vitro system, so findings should be treated as model-specific until supported by complementary evidence from organoids, animal models, or clinical samples. This validation helps distinguish generalizable mechanisms from cell-line behavior.
A typical study cultures the adherent cells, applies a defined treatment or other experimental condition, and measures a relevant outcome. Depending on the question, investigators can track growth, migration, invasive behavior, EMT-related changes, drug resistance, or treatment response. Aligning the measured endpoint with the hypothesis makes the model informative rather than purely descriptive.
They support preclinical screening of targeted and cytotoxic therapies by allowing investigators to compare how this pancreatic cancer model responds to different treatments. Studies can also examine drug resistance, helping determine whether cells show sensitivity or resistant behavior. These experiments are useful for prioritizing mechanisms or candidate treatments for further validation, not for replacing clinical evidence.
Their value extends to interconnected cancer phenotypes, including oncogenic signaling, proliferation, epithelial-to-mesenchymal transition, migration, invasion, drug resistance, and therapeutic response. This breadth allows researchers to connect a molecular alteration such as KRAS G12D with measurable tumor-cell behaviors, while comparison with more complex models clarifies which observations apply beyond the cell line.